References
- ASAM. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020;14:1–91. doi:https://doi.org/10.1097/ADM.0000000000000633.
- Alkermes Inc. VIVITROL (naltrexone for extended-release injectable suspension) Prescribing Information; 2020.
- Soyka M, Zingg C, Koller G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008;11:641–53. doi:https://doi.org/10.1017/S146114570700836X.
- Bisaga A, Mannelli P, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: a phase 3 randomized trial. Drug Alcohol Depend. 2018;187:171–78. doi:https://doi.org/10.1016/j.drugalcdep.2018.02.023.
- Comer SD, Mannelli P, Alam D, Douaihy A, Nangia N, Akerman SC, Zavod A, Silverman BL, Sullivan MA. Transition of patients with opioid use disorder from buprenorphine to extended-release naltrexone: a randomized clinical trial assessing two transition regimens. Am J Addict. 2020;29:313–22. doi:https://doi.org/10.1111/ajad.13024.
- Cicero TJ, Ellis MS. The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse. Dialogues Clin Neurosci. 2017;19:259–69.
- Dunn K, Bergeria C, Huhn AS, Strain EC. Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome. Drug Alcohol Depend. 2020;215:108212. doi:https://doi.org/10.1016/j.drugalcdep.2020.108212.
- Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther. 2020;45:892–903. doi:https://doi.org/10.1111/jcpt.13114.
- Stein MD, Conti MT, Herman DS, Anderson BJ, Bailey GL, Noppen DV, Abrantes AM. Worries about discontinuing buprenorphine treatment: scale development and clinical correlates. Am J Addict. 2019;28:270–76. doi:https://doi.org/10.1111/ajad.12884.
- Bisaga A, Mannelli P, Sullivan MA, Vosburg SK, Compton P, Woody GE, Kosten TR. Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies. Am J Addict. 2018;27:177–87. doi:https://doi.org/10.1111/ajad.12711.
- Northrup TF, Stotts AL, Green C, Potter JS, Marino EN, Walker R, Weiss RD, Trivedi M. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model. Addict Behav. 2015;41:20–28. doi:https://doi.org/10.1016/j.addbeh.2014.09.021.
- SAMHSA. 2020. TIP 63: medications for opioid use disorder. [accessed 2021 Jan]. https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP20-02-01-006.
- Mannelli P, Swartz M, Wu LT. Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone. Am J Addict. 2018;27:471–76. doi:https://doi.org/10.1111/ajad.12763.
- Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, Hu MC, Boney TY, Wilson D, O’Brien CP. Relapse to opioid use disorder after inpatient treatment: protective effect of injection naltrexone. J Subst Abuse Treat. 2018;85:49–55. doi:https://doi.org/10.1016/j.jsat.2017.04.016.
- Sullivan MA, Bisaga A, Glass A, Mishlen K, Pavlicova M, Carpenter KM, Mariani JJ, Levin FR, Nunes EV. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug Alcohol Depend. 2015;147:122–29. doi:https://doi.org/10.1016/j.drugalcdep.2014.11.028.
- Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a cascade of care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45:1–10. doi:https://doi.org/10.1080/00952990.2018.1546862.
- Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence. Cochrane Database Syst Rev. 2005;CD004580. doi:https://doi.org/10.1002/14651858.CD004580.pub2.